Whitepaper: Upstream process intensification
Posted: 5 February 2021 | Merck | No comments yet
Strategies for upstream process intensification can be leveraged for cell line development, the seed train, production and cell culture media formulation.
The Facility of the Future represents a transformation in how biologics are developed and manufactured. Upstream intensification is one strategy that will enable this revolution by significantly driving down costs through an increase in volumetric productivity.
Related content from this organisation
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
- Market outlook to 2032: future trends across the seven major markets
Related topics
Biologics, Biopharmaceuticals, Bioprocessing, Biosimilars, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Lab Automation, Manufacturing